Answers are grounded in this paper and cite their sources.
Shows that dupilumab reduces tissue eosinophils in patients with nasal polyps, indicating improved outcomes.
Summary Dupilumab reduces tissue eosinophils in nasal polyps beyond improving clinical and endoscopic outcomes. Dupilumab treatment is associated with a reduction of tissue inflammatory eosinophils that correlates with higher clinical and endoscopic improvement.
No takes yet. Share an insight, caveat, or question.
Vultaggio et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: